Renub Research has recently published a report titled "United States Biopsy Market, Size, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis," providing a comprehensive analysis of the industry that includes market share insights. In addition, the report comprises competitor and regional research and contemporary extension in the United States Biopsy Market. The United States Biopsy Industry shall expand at a CAGR of nearly 4.46% from 2023 to 2028.

1. United States Biopsy Market
will be around US$ 21.41
Billion in 2028
Base Year: 2022
Market Research & Advisory

2. 2
2
United States Biopsy Market
Renub Research has recently published a report titled "United States Biopsy Market, Size, Forecast 2023-2028,
Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis," providing a comprehensive
analysis of the industry that includes market share insights. In addition, the report comprises competitor and regional
research and contemporary extension in the United States Biopsy Market. The United States Biopsy Industry shall
expand at a CAGR of nearly 4.46% from 2023 to 2028. A biopsy is a medical procedure involving taking a tissue or
cell sample from the body to diagnose or rule out cancer, infections, or other conditions. It can be performed using a
needle or surgical techniques, depending on the location of the tissue and the reason for the biopsy.
The growing prevalence of cancer has resulted in an augmented need for diagnostics procedures, including
biopsies, thereby contributing to the expansion of the United States' biopsy market. The American Cancer Society
projects that approximately 1.9 million new cancer cases (equivalent to around 5,370 cases per day) and 609,820
cancer-related fatalities (about 1,670 deaths each day) will occur in the United States 2023.
The demand for less invasive procedures is increasing as patients are becoming more inclined towards procedures
that offer benefits such as faster recovery and reduced risks compared to traditional surgical methods, thereby
fuelling the growth of the United States biopsy market. Moreover, the increasing recognition of the significance of
early cancer detection is also playing a crucial role in the surging demand for biopsies.
2
https://www.renub.com

3. 3
3
United States Biopsy Market
Biopsy technology has undergone noteworthy advancements, resulting in increased
precision and reduced invasiveness of the procedure. The utilization of image-guided
biopsies, including ultrasound or CT-guided biopsies, is an exemplar of these advancements,
which has contributed to enhancing the accuracy and safety of the procedure.
The high incidence and mortality rate of lung cancer, along with the increased use of
low-dose CT screening, have contributed to the prominence of lung cancer in the
United States Biopsy Market
Lung cancer is one of the highly prevalent cancers in the United States, with a high
incidence rate and mortality rate. According to the American Cancer Society's projections
for 2023, there will be approximately 238,340 new lung cancer cases in the United States,
with 117,550 cases in men and 120,790 cases in women. Furthermore, an estimated
127,070 deaths from lung cancer shall occur in the same year, with 67,160 deaths in men
and 59,910 deaths in women.
3
https://www.renub.com

4. 4
Obtaining a tissue sample through biopsy is necessary for accurate diagnosis and treatment planning of lung cancer
due to the difficulty in diagnosing the disease without it. Moreover, the rising utilization of low-dose CT screening in
high-risk populations has resulted in the discovery of more suspicious nodules, often necessitating a biopsy for
diagnosis. Additionally, the demand for precise diagnosis through biopsy has increased due to the development of
targeted therapies for specific lung cancer mutations, requiring molecular tissue testing to determine treatment
decisions.
Rising incidence of breast cancer and a shift towards more conservative diagnostics approaches have
driven the growth in the United States biopsy market for breast cancer
Due to the growing incidence of breast cancer in women in the United States, there has been a surge in the volume
of women referred for diagnostic tests, including biopsies. The American Cancer Society projects that in 2023,
nearly 297,790 new cases of invasive breast cancer and diagnosis of 55,720 new cases of ductal carcinoma in situ
(DCIS) will be in women in the country, with about 43,700 women expected to die from breast cancer. With more
women being aware of and screening for breast cancer, more cases are being detected at earlier stages, leading to
an increase in the number of women undergoing biopsies as part of the diagnostics process.
4
https://www.renub.com
4
United States Biopsy Market

5. Improved breast imaging technology has led to the increased detection of suspicious
breast lesions, which often require biopsy for confirmation or exclusion of cancer.
Moreover, there has been a trend toward less invasive diagnostic methods prioritizing
biopsy over surgical tissue removal, especially for small and non-palpable lesions,
resulting in faster and more cost-effective results.
𝑭𝒐𝒓 𝑴𝒐𝒓𝒆 𝑫𝒆𝒕𝒂𝒊𝒍𝒔, 𝑮𝒓𝒂𝒃 𝒕𝒉𝒆 Free Sample Report: https://www.renub.com/request-
sample-page.php?gturl=united-states-biopsy-testing-market-and-volume-analysis-to-
2020-511-p.php
Competitive Landscape:
Some key companies operating in the region are Becton Dickenson & Company,
Braun Melsungen AG (Germany), Cardinal Health Inc., Medtronic Plc., Hologic
Inc., Bio-Rad Laboratories Inc., Quest Diagnostics, Thermo Fisher Scientific
Inc., Roche Diagnostics, and Myriad Genetics Inc.
5
https://www.renub.com
5
United States Biopsy Market

6. The competition in the United States biopsy market stems from the availability of different biopsies, each with
distinct advantages and disadvantages offered by providers, creating a competitive environment. Additionally, the
demand for biopsy equipment and supplies is competitive due to the numerous manufacturers. Moreover, there is
fierce competition among healthcare providers, such as hospitals, clinics, and specialty centers, who offer biopsy
services. Lastly, the growing demand for biopsies has increased the number of providers in the market, further
intensifying the competition.
Market Summary:
• Market Segment – By market segment, the United States Biopsy Market, breakup in 8 viewpoints (Breast
Cancer, Prostate Cancer, Lung Cancer, Liver Cancer, Thyroid Cancer, Kidney Cancer, Colorectal Cancer, and
Melanoma Cancer).
• Key Players – All the major players have been covered from 3 Viewpoints (Overview, Recent Developments, and
Sales Analysis) Becton Dickenson & Company, Braun Melsungen AG (Germany), Cardinal Health Inc., Medtronic
Plc., Hologic Inc., Bio-Rad Laboratories Inc., Quest Diagnostics, Thermo Fisher Scientific Inc., Roche
Diagnostics, and Myriad Genetics Inc.
6
https://www.renub.com
6
United States Biopsy Market

7. S
O U T
A U
B
7
https://www.renub.com
Renub Research is a Market Research and Information Analysis company with more than 14 years of experience in
Research, Survey, and Consulting. Our research helps companies to take business decisions: on strategy,
organization, operations, technology, mergers & acquisitions, etc. Till now we have published more than 7000
syndicated reports and worked on more than 500 custom research projects. Currently, we are supplying data to
EMIS, Bloomberg, Thomson Reuters, etc. We support many blue-chip companies by providing them with findings
and perspectives across a wide range of markets.
Media Contact:
Company Name: Renub Research
Contact Person: Rajat Gupta, Marketing Manager
Phone No: +1-478-202-3244 | +91-120-421-9822 (IND)
Address: 225 Kristie Ln, Roswell, GA 30076
Email: info@renub.com
LinkedIn: https://linkedin.com/company/renub-research